Final analysis from the phase 2 OVATION 2 trial (NCT03393884) has demonstrated a continued and growing overall survival (OS) ...

Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with ...

Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the ...

Dr. Gail Roboz from Weill Cornell Medicine and Dr. Gabriel Mannis from Stanford University explored the evolving landscape of ...

Combining durvalumab (Imfinzi) with stereotactic body radiotherapy (SBRT) appeared to reduce tumor progression among patients ...

Richardson, MD, detailed the strategic integration of mezigdomide into several areas including the unmet need of post CAR ...

Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment ...

Phase 2b data show RAD101 amino acid PET hits 90% concordance, helping distinguish brain metastasis recurrence from ...

When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...

Theriva Biologics has received FDA agreement on the core design elements of a pivotal phase 3 trial evaluating zabilugene ...

Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...